SLC3A2 protein levels were stable in untreated NB cell lines, however, addition of lorlatinib resulted in a significant decrease in the half-life of SLC3A2 to 7.6 ± 0.96 h in CLB-BAR, 5.5 ± 0.83 h in CLB-GE, and 6.2 ± 0.83 h in CLB-GAR (Fig. 1E, Sup. Here, SLC3A2 is linked to neuroblastoma.